Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric long-term safety surveillance of ciprofloxacin versus non-quinolone antibiotics
2014-004622-18Phase 3
- Sponsor
- Bayer
- Start
- Jan 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ciprofloxacin in bacterial disease and Infectious disease (2 arms), sponsored by Bayer. Primary endpoints: Long-term incidence of arthropathy and musculoskeletal sequelae and Short- and long-term neurological tolerability.
02
Drugs
ciprofloxacin
03
Conditions
bacterial diseaseInfectious disease
Beyond the preview
Go deeper on 2014-004622-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004622-18.